Thrombotic Thrombocytopenic Purpura Therapeutics: Europe Acknowledges Sanofi's Cablivi as Potent Drug
Surged incidences of fatality triggered by blood disorders such as thrombotic thrombocytopenic purpura has influenced substantial advancement in apt therapeutics development. Alternatively known as moschcowitz disease, thrombotic thrombocytopenic purpura restricts blood clotting thus resulting in decreased blood platelet count. Deficient ADAMTS13, a blood clotting enzyme is attributed as the main trigger for thrombotic thrombocytopenic purpura.
View full press release